MetaADEDB 2.0 @ LMMD
roxatidine acetate
(SMTZFNFIKUPEJC-UHFFFAOYSA-N)
Structure
SMILES
O=C(COC(=O)C)NCCCOc1cccc(c1)CN1CCCCC1
Type(s)
Experimental
ATC code(s)
A02BA06
Molecular Formula:
C19H28N2O4
Molecular Weight:
348.437
Log P:
2.4495
Hydrogen Bond Acceptor:
6
Hydrogen Bond Donor:
1
TPSA:
67.87
CAS Number(s):
78628-28-1
Synonym(s)
1.
roxatidine acetate
2.
Roxiwas
3.
Zarocs
4.
roxatidine
5.
roxatidine acetate hydrochloride
External Link(s)
MeSHC053742
PubChem Compound5105
BindingDB50404032
ChEBI94758
CHEMBLCHEMBL46102
DrugBankDB08806
DrugCentral2408
KEGGdr:D08495
ZINC3812908
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Drug ineffectiveFAERS: 1US FAERS
2Product quality issueFAERS: 1US FAERS
3AbasiaOFFSIDES
4Abdominal symptomOFFSIDES
5Acute myocardial infarctionOFFSIDES
6Adenomatous Polyposis ColiOFFSIDES
7Adnexa uteri massOFFSIDES
8Alanine Aminotransferase IncreasedOFFSIDES
9AlveolitisOFFSIDES
10AnorexiaOFFSIDES
11Antinuclear antibody increasedOFFSIDES
12AnuriaOFFSIDES
13ApathyOFFSIDES
14Autoimmune hepatitisOFFSIDES
15Bacterial pyelonephritisOFFSIDES
16BedriddenOFFSIDES
17Blood GlucoseOFFSIDES
18Blood albumin decreasedOFFSIDES
19Blood alkaline phosphatase increasedOFFSIDES
20Blood brain barrier defectOFFSIDES
21Blood chloride decreasedOFFSIDES
22Blood creatine phosphokinase increasedOFFSIDES
23Blood creatinine increasedOFFSIDES
24Blood fibrinogen increasedOFFSIDES
25Blood gases abnormalOFFSIDES
26Blood immunoglobulin A increasedOFFSIDES
27Blood immunoglobulin G increasedOFFSIDES
28Blood lactate dehydrogenase increasedOFFSIDES
29Blood potassium decreasedOFFSIDES
30Blood sodiumOFFSIDES
31Blood triglycerides increasedOFFSIDES
32Blood urea increasedOFFSIDES
33Blood uric acidOFFSIDES
34Brain AbscessOFFSIDES
35Brain natriuretic peptide increasedOFFSIDES
36Catheter site painOFFSIDES
37Chemotherapeutic drug level increasedOFFSIDES
38CirrhosisOFFSIDES
39Concomitant disease progressionOFFSIDES
40Cytomegalovirus test positiveOFFSIDES
41Depressed Level of ConsciousnessOFFSIDES
42Disseminated Intravascular CoagulationOFFSIDES
43DizzinessOFFSIDES
44DrowsinessOFFSIDES
45DyspepsiaOFFSIDES
46Eosinophil percentage increasedOFFSIDES
47Eosinophilic myocarditisOFFSIDES
48Epidural AbscessOFFSIDES
49Escherichia infectionOFFSIDES
50Eyelid Function DisorderOFFSIDES
51Feeling abnormalOFFSIDES
52Fluid overloadOFFSIDES
53Gamma-Glutamyltransferase IncreasedOFFSIDES
54Gastric Antral Vascular EctasiaOFFSIDES
55Gastric ulcerOFFSIDES
56General physical health deteriorationOFFSIDES
57Genital tract inflammationOFFSIDES
58GlobulinuriaOFFSIDES
59Haptoglobin DecreasedOFFSIDES
60HypoxiaOFFSIDES
61Injury asphyxiationOFFSIDES
62Large intestine perforationOFFSIDES
63Leukopenia neonatalOFFSIDES
64Lymphocyte count decreasedOFFSIDES
65Markedly reduced dietary intakeOFFSIDES
66NasopharyngitisOFFSIDES
67NauseaOFFSIDES
68Nephrotic SyndromeOFFSIDES
69Neutrophil count decreasedOFFSIDES
70Nutritional condition abnormalOFFSIDES
71Oculomucocutaneous syndromeOFFSIDES
72OliguriaOFFSIDES
73OsteoporosisOFFSIDES
74Pancreatic carcinoma recurrentOFFSIDES
75Peptic Ulcer20586863
21805066		CTD
76Percutaneous Coronary InterventionOFFSIDES
77PericarditisOFFSIDES
78Pneumocystis jiroveci pneumoniaOFFSIDES
79PolymyositisOFFSIDES
80Protein total decreasedOFFSIDES
81PsoriasisOFFSIDES
82Pyoderma GangrenosumOFFSIDES
83Red blood cell schistocytes presentOFFSIDES
84Renal salt-wasting syndromeOFFSIDES
85Respiratory FailureOFFSIDES
86RhabdomyolysisOFFSIDES
87Scleroderma renal crisisOFFSIDES
88SclerodermaOFFSIDES
89Septic ShockOFFSIDES
90Subcutaneous EmphysemaOFFSIDES
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.